ACIU
$2.85-0.10 (-3.39%)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Recent News
AC Immune (ACIU) Upgraded to Buy: Here's Why
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?
Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
AC Immune: Q4 Earnings Snapshot
LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Friday reported a loss of $18 million in its fourth quarter. The Lausanne, Switzerland-based company said it had a loss of 18 cents per share. The biopharmaceutical company posted revenue of $423,000 in the period.
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial.
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0